Preventing Venous Thromboembolism in Ambulatory Patients with Cancer: A Narrative Review

Cancers
Anne RosselChristophe Marti

Abstract

Venous thromboembolism (VTE) is frequent among patients with cancer. Ambulatory cancer patients starting chemotherapy have a 5% to 10% risk of cancer associated thrombosis (CAT) within the first year after cancer diagnosis. This risk may vary according to patient characteristics, cancer location, cancer stage, or the type of chemotherapeutic regimen. Landmark studies evaluating thrombophrophylaxis with low molecular weight heparin (LMWH) for ambulatory cancer patients have shown a relative reduction in the rate of symptomatic VTE of about one half. However, the absolute risk reduction is modest among unselected patients given a rather low risk of events resulting in a number needed to treat (NNT) of 40 to 50. Moreover, this modest benefit is mitigated by a trend towards an increased risk of bleeding, and the economic and patient burden due to daily injections of LMWH. For these reasons, routine thromboprophylaxis is not recommended by expert societies. Advances in VTE risk stratification among cancer patients, and growing evidence regarding efficacy and safety of direct oral anticoagulants (DOACs) for the treatment and prevention of CAT have led to reconsider the paradigms of this risk-benefit assessment. This narrative review ...Continue Reading

References

Aug 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A P ChahinianR L Comis
Nov 18, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L H MaurerM R Green
Jun 1, 2002·Archives of Internal Medicine·John A HeitL Joseph Melton
May 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ajay K KakkarRobin C N Williamson
Feb 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Clara P W KlerkHarry R Büller
Feb 11, 2005·JAMA : the Journal of the American Medical Association·Jeanet W BlomFrits R Rosendaal
Mar 1, 2006·Archives of Internal Medicine·Helen K ChewRichard H White
Apr 6, 2007·Journal of Thrombosis and Haemostasis : JTH·A Lazo-LangnerM A Rodger
Aug 4, 2009·PLoS Pathogens·Yoshitaka SatoTatsuya Tsurumi
Mar 31, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toni K ChoueiriJoaquim Bellmunt
Sep 11, 2010·Blood·Cihan AyIngrid Pabinger
Feb 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboMario Boccadoro
Apr 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frederiek F van DoormaalHarry R Buller
Nov 22, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A MaraveyasG Bozas
Jan 14, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F PetrelliS Barni
Jan 26, 2012·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Sylvia K HaasUNKNOWN TOPIC Investigators
Feb 18, 2012·The New England Journal of Medicine·Giancarlo AgnelliUNKNOWN SAVE-ONCO Investigators
Nov 14, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alex J WalkerMatthew J Grainge
Jan 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanUNKNOWN American Society of Clinical Oncology
May 20, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Uwe PelzerHanno Riess
Dec 25, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fergus MacbethGareth Griffiths
Dec 3, 2016·The Cochrane Database of Systematic Reviews·Marcello Di NisioAnne Ws Rutjes
Apr 21, 2017·The Oncologist·Chiara Alessandra CellaSabino De Placido
Dec 13, 2017·The New England Journal of Medicine·Gary E RaskobUNKNOWN Hokusai VTE Cancer Investigators
May 11, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Annie M YoungMark Levine
Dec 5, 2018·The New England Journal of Medicine·Marc CarrierUNKNOWN AVERT Investigators
Jan 5, 2019·Haematologica·Frits I MulderUNKNOWN CAT-prediction collaborators
Feb 8, 2019·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN ANNEXA-4 Investigators
Feb 21, 2019·The New England Journal of Medicine·Alok A KhoranaUNKNOWN CASSINI Investigators

❮ Previous
Next ❯

Citations

Nov 25, 2020·ESMO Open·Alok A KhoranaPhilipS Wells

❮ Previous
Next ❯

Software Mentioned

AVERT
CASSINI

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.